Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Case report of a KIT-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy

Tytuł:
Case report of a KIT-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy
Autorzy:
Luo C
Shen JY
Ying J
Fang XH
Wang XH
Fu ZX
Liu P
Temat:
advanced melanoma
KIT mutation
Apatinib
Temozolomide
combination therapy
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło:
OncoTargets and Therapy, Vol Volume 10, Pp 4553-4557 (2017)
Wydawca:
Dove Medical Press, 2017.
Rok publikacji:
2017
Kolekcja:
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
1178-6930
Relacje:
https://www.dovepress.com/case-report-of-a-kit-mutated-melanoma-patient-with-an-excellent-respon-peer-reviewed-article-OTT; https://doaj.org/toc/1178-6930
Dostęp URL:
https://doaj.org/article/1a1ea7a988f84820aae2baa4f836f982  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.1a1ea7a988f84820aae2baa4f836f982
Czasopismo naukowe
Cong Luo,1 Jiayu Shen,2 Jieer Ying,1 Xianhua Fang,3 Xiaohong Wang,1 Zhixuan Fu,4 Peng Liu5 1Department of Abdominal Oncology, Zhejiang Cancer Hospital, 2The Second Clinical Medical College, Zhejiang Chinese Medical University, 3Department of Pathology, 4Department of Colorectal Surgery, 5Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China Abstract: Malignant melanoma is one kind of malignant disease which has high rates of mortality, metastasis, and poor prognosis. The therapeutic landscape is rapidly changing with the development of novel agents in recent decades, such as anti-PD-1 agents, anti-CTLA-4 agents, and BRAF inhibitors. However, since most of these novel agents are very expensive, not all patients can afford them. Apatinib is a novel oral small-molecule tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2) and may also be effective on Ret, c-KIT, and c-src. Temozolomide (TMZ) is a second-generation alkylating agent and a cytotoxic drug for melanoma treatment. In this work, we reported a case of metastatic melanoma with an excellent response to apatinib/TMZ combination therapy with progression-free survival for more than one year. This patient showed high expression of CD117, VEGFR-3, and KIT mutation in exon 11, suggesting that apatinib may induce clinical response via inhibiting VEGFR and c-KIT. Apatinib/TMZ combination therapy could be a new option for the treatment of advanced melanoma with KIT mutation. Keywords: advanced melanoma, KIT mutation, apatinib, temozolomide, combination therapy

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies